Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C

Summary Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests of liver fibrosis and cross‐sectional studies have shown their combination significantly improves diagnostic accuracy. Aim To compare the prognostic accuracy of six blood fibrosis tests and liver biopsy, and evaluate if test combination improves the liver‐prognosis assessment in chronic hepatitis C (CHC). Methods A total of 373 patients with compensated CHC, liver biopsy (Metavir F) and blood tests targeting fibrosis (APRI, FIB4, Fibrotest, Hepascore, FibroMeter) or cirrhosis (CirrhoMeter) were included. Significant liver‐related events (SLRE) and liver‐related deaths were recorded during follow‐up (started the day of biopsy). Results During the median follow‐up of 9.5 years (3508 person‐years), 47 patients had a SLRE and 23 patients died from liver‐related causes. For the prediction of first SLRE, most blood tests allowed higher prognostication than Metavir F [Harrell C‐index: 0.811 (95% CI: 0.751–0.868)] with a significant increase for FIB4: 0.879 [0.832–0.919] (P = 0.002), FibroMeter: 0.870 [0.812–0.922] (P = 0.005) and APRI: 0.861 [0.813–0.902] (P = 0.039). Multivariate analysis identified FibroMeter, CirrhoMeter and sustained viral response as independent predictors of first SLRE. CirrhoMeter was the only independent predictor of liver‐related death. The combination of FibroMeter and CirrhoMeter classifications into a new FM/CM classification improved the liver‐prognosis assessment compared to Metavir F staging or single tests by identifying five subgroups of patients with significantly different prognoses. Conclusions Some blood fibrosis tests are more accurate than liver biopsy for determining liver prognosis in CHC. A new combination of two complementary blood tests, one targeted for fibrosis and the other for cirrhosis, optimises assessment of liver‐prognosis.